VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Public ClinicalTrials.gov record NCT05156125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative Colitis
Study identification
- NCT ID
- NCT05156125
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Oppilan Pharma Ltd
- Industry
- Enrollment
- 213 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- VTX002 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2021
- Primary completion
- Aug 29, 2023
- Completion
- Mar 12, 2025
- Last update posted
- Apr 29, 2026
2021 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Site # 840030 | Garden Grove | California | 92845 | — |
| Local Site # 840026 | Lancaster | California | 93534 | — |
| Local Site # 840040 | San Diego | California | 92123 | — |
| Local Site # 840001 | Ventura | California | 93003 | — |
| Local Site # 840049 | Kissimmee | Florida | 34744 | — |
| Local Site # 840006 | Miami | Florida | 33165 | — |
| Local Site # 840018 | Atlanta | Georgia | 30342 | — |
| Local Site # 840046 | New Albany | Indiana | 47150 | — |
| Local Site # 840042 | Shreveport | Louisiana | 71105 | — |
| Local Site # 840044 | Ypsilanti | Michigan | 48197 | — |
| Local Site # 840043 | Dayton | Ohio | 45415 | — |
| Local Site # 840010 | Oklahoma City | Oklahoma | 73101 | — |
| Local Site # 840045 | Myrtle Beach | South Carolina | 29572 | — |
| Local Site # 840013 | Garland | Texas | 75044 | — |
| Local Site # 8400039 | Lubbock | Texas | 79424 | — |
| Local Site # 840033 | McAllen | Texas | 78503 | — |
| Local Site # 840007 | San Marcos | Texas | 78666 | — |
| Local Site # 840016 | Southlake | Texas | 76092 | — |
| Local Site # 840028 | Tyler | Texas | 75701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05156125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05156125 live on ClinicalTrials.gov.